Lack of aspirin-induced decrease in thrombin formation in subjects resistant to aspirin.
Undas
Anetta
A
Placzkiewicz-Jankowska
Ewa
E
Zieliński
Lukasz
L
Tracz
Wieslawa
W
D001241:Aspirin / Q000494:pharmacology / Q000627:therapeutic use*; D001760:Bleeding Time; D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D004351:Drug Resistance; D006801:Humans; D008297:Male; D008833:Microcirculation / Q000293:injuries; D008875:Middle Aged; D010446:Peptide Fragments / Q000097:blood; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D011516:Prothrombin; D012307:Risk Factors; D013917:Thrombin / Q000378:metabolism*; D013929:Thromboxane B2 / Q000097:blood
D010446:Peptide Fragments; D010975:Platelet Aggregation Inhibitors; C045879:prothrombin fragment 1.2; D013929:Thromboxane B2; D011516:Prothrombin; D013917:Thrombin; D001241:Aspirin